ACD Labs Logo


The Impact of a Biotransformation Database on "Intelligent" Drug Design

June 17, 2020, 10:00 EDT | 16:00 CET

Presented by:
Emre Isin (Director, Head of Biotransformation and Enzymology, UCB Biopharma SRL)
Martin Hayes (Biocatalysis Leader, Hit Discovery, AstraZeneca, Sweden)

The knowledge generated in metabolite identification studies can provide valuable insights for intelligent drug design, and the maximum value from these studies can be harvested only if the data are stored and easily accessible within the organization. Similarly, synthetic reactions, forced degradation/stability studies, impurity identification, structural characterization, environmental stability studies and many other activities generate chemical structure data that can inform R&D. Are scientists in your organization getting maximum value from research activities?

Join Emre Isin (UCB) and Martin Hayes (AstraZeneca) to hear their reasoning behind, and experience of, creating organizational value from metabolite identification data. From the initial build of a metabolite database in 2008 at AstraZeneca to a more recent deployment at UCB, learn about:

  • The importance of storing chemical structural transformation knowledge in chemically intelligent software
  • Benefits gleaned from accessible, searchable biotransformation data at UCB and AstraZeneca
  • Harnessing today's R&D efforts for future applications (data science and AI)
The Impact of a Biotransformation Database on Intelligent Drug Design

Register Now

First Name
Last Name


Emre Isin

Dr. Emre M. Isin, Director, Head of Biotransformation and Enzymology, UCB Biopharma SRL

Martin Hayes

Martin Hayes, Biocatalysis Leader, Hit Discovery, AstraZeneca, Sweden


Sanji Bhal

Sanji Bhal, Director of Marketing & Communications, ACD/Labs